EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Comparative effectiveness and safety of leflunomide versus methotrexate in the treatment of elderly rheumatoid arthritis patients: A retrospective cohort study

Esra Dilsat Imrak iD, Ilknur Aktas, Alev Cetin Duran iD

Sage Open Chronic Disease · 2026-02 · 17

DOI: 10.1177/27558428261463661 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Sage Open Chronic Disease, online erschienen am 08.07.2026. Verfasst von Esra Dilsat Imrak und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Balıkesir Ataturk City Hospital, Turkey. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The comparative effectiveness and safety of leflunomide and methotrexate in elderly rheumatoid arthritis (RA) patients remain understudied despite the growing prevalence of RA in this population.

Objective

To compare the efficacy, drug survival, and safety of leflunomide and methotrexate in disease-modifying antirheumatic drugs (DMARD)-naive RA patients aged ⩾65 years.

Design

Retrospective cohort study.

Methods

Patients aged ⩾65 years with RA who were treated initially with either leflunomide or methotrexate were analyzed. Patients with DMARD-naive RA were selected according to the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Patients received at least 6 months of treatment and were followed up for 24 weeks. Disease activity was assessed using the Disease Activity Score 28 (DAS28)-CRP (remission: DAS28-CRP < 2.6 and low disease activity (LDA): DAS28-CRP 2.6–3.2). Drug survival and adverse events were also recorded.

Results

This study included 167 patients (80 on leflunomide and 87 on methotrexate). Methotrexate led to a greater reduction in DAS28-CRP (median reduction 1.9 vs 0.7, p < 0.001). By contrast, remission (37.9% vs 31.3%, p = 0.229) and LDA rates (82.8% vs 73.8%, p = 0.110) were not significantly different. In both groups, swollen joint count was associated with remission ( p < 0.001). Drug survival rates were comparable in the unadjusted analysis (74.7% vs 66.3%, p = 0.152). After adjusting for baseline disease activity, methotrexate was associated with a 73% lower hazard of discontinuation (adjusted hazard ratio 0.27, 95% confidence interval [CI] 0.13–0.54, p < 0.001). The adverse event-related discontinuation rate was low and similar between the groups (10% for leflunomide vs 8% for methotrexate, p = 0.431).

Conclusion

Both leflunomide and methotrexate are effective and safe in elderly RA patients. Methotrexate was associated with a greater reduction in disease activity and better adjusted drug survival. However, given the baseline differences in disease activity and the lack of statistically significant differences in remission and low disease activity rates at week 24, methotrexate remains a reasonable first-line option in the absence of contraindications for elderly RA patients. Leflunomide is a viable alternative when methotrexate is not tolerated.

Schlagwörter

Stichwörter der Autor:innen

effectivenesselderlyleflunomidemethotrexaterheumatoid arthritissafety

Autor:innen und Institutionen

  • Department of Rheumatology, Balıkesir Ataturk City Hospital, Turkey.
  • Department of Physical Medicine and Rehabilitation, University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Turkey.
  • Department of Medical Microbiology and Basic Immunology, Balıkesir Ataturk City Hospital, Turkey.

ORCID-Profile: Esra Dilsat Imrak, Alev Cetin Duran

Zitieren

APA

Imrak, E. D., Aktas, I., & Cetin Duran, A. (2026). Comparative effectiveness and safety of leflunomide versus methotrexate in the treatment of elderly rheumatoid arthritis patients: A retrospective cohort study. Sage Open Chronic Disease, 17. https://doi.org/10.1177/27558428261463661

Vancouver

Imrak ED, Aktas I, Cetin Duran A. Comparative effectiveness and safety of leflunomide versus methotrexate in the treatment of elderly rheumatoid arthritis patients: A retrospective cohort study. Sage Open Chronic Disease. 2026;17. doi:10.1177/27558428261463661

BibTeX
@article{Imrak2026,
  author = {Imrak, Esra Dilsat and Aktas, Ilknur and Cetin Duran, Alev},
  title = {Comparative effectiveness and safety of leflunomide versus methotrexate in the treatment of elderly rheumatoid arthritis patients: A retrospective cohort study},
  journal = {Sage Open Chronic Disease},
  year = {2026},
  volume = {17},
  doi = {10.1177/27558428261463661}
}
Kostenlos starten →